We keep track of the latest news on global drug R&D, approvals, policies and market trends. Follow new drug progress and regulatory updates, and deliver authoritative and timely pharmaceutical information for professionals.
On May 25, 2026, the 11th National Centralized Drug Procurement results were fully implemented across public hospitals nationwide, covering 55
On May 22, 2026, the Japanese MHLW expert committee formally approved TeroMira, developed by Oncolys Biopharma, for esophageal cancer, making
On March 27, 2026, AstraZeneca announced tezepelumab injection (Tezspire®) received full NMPA approval in China for maintenance treatment of severe
In April 2026, relafusp alfa injection (Aizeli), a Class 1 innovative drug independently developed by Hengrui Medicine, was approved by
On May 22, 2026, the Japanese MHLW expert committee formally approved TeroMira, developed by Oncolys Biopharma, for esophageal cancer, making
On May 25, 2026, the 11th National Centralized Drug Procurement results were fully implemented across public hospitals nationwide, covering 55
Since the beginning of 2026, the global pharmaceutical industry has accelerated across drug R&D, clinical breakthroughs, regulatory approvals and technological
Early June 2026 has witnessed a flurry of global approvals and clinical data releases, with multiple practice-changing advances. Below is
In early June 2026, the China NMPA granted conditional approval for lobrutinib tablets (LuKeda®) in adult patients with relapsed or
On May 22, 2026, the U.S. FDA granted accelerated approval to Gilead Sciences’ Hepcludex (bulevirtide) for chronic hepatitis D (HDV)
